Lipid Guidelines Broaden Beyond LDL to Focus on Lifetime Cardiovascular Risk

A new narrative review in Cardiology and Therapy argues that prevention of atherosclerotic cardiovascular disease is entering a major shift. The authors, Andrew Carlson, Zaid A. Zayyad, Adhir R. Shroff and colleagues, draw on literature through April 2026, including guidelines, randomized trials and observational research, to show that lipid management is moving away from an exclusive focus on low-density lipoprotein cholesterol and toward a broader approach that also weighs apolipoprotein B, triglycerides and lipoprotein(a).

The case for this change is rooted in the cumulative biology of atherosclerosis. Longer exposure to LDL cholesterol is linked to higher cardiovascular risk, and people with greater LDL exposure earlier in life tend to face higher coronary artery disease risk even if their midlife levels are similar. Across several therapy trials, the size of coronary risk reduction has tracked with the amount of LDL lowered. A 2016 meta-regression found that every 38.7 mg/dl drop in LDL corresponded to relative cardiovascular risks of 0.77 with statins and 0.75 with established non-statin treatments. In a Danish study that compared patients above and below age 70, the same LDL reduction was associated with a 23 percent fall in hospitalizations for acute coronary syndrome, non-hemorrhagic stroke and coronary revascularization in both age groups.

One of the biggest changes described in the review is the updated 2026 American College of Cardiology/American Heart Association dyslipidemia guideline. It replaces the pooled cohort equations with the PREVENT-ASCVD model, which estimates both 10-year and 30-year risk for total cardiovascular disease beginning at age 30 and incorporates risk-enhancing factors such as metabolic syndrome, chronic kidney disease and lipoprotein(a). The guideline also recommends measuring Lp(a) once in a lifetime for everyone, supports apolipoprotein B testing in selected cases to assess residual risk, and uses coronary artery calcium scoring as an important tool when statin decisions are uncertain in borderline and intermediate-risk patients. By comparison, European Society of Cardiology and European Atherosclerosis Society guidance uses predefined SCORE2 and SCORE2-OP risk categories to set LDL targets, with Lp(a) and calcium scoring mainly used to move patients between categories.

The review says lifetime risk estimation is needed because short-term calculators often miss danger. More than half of adults who appear low risk over 10 years for ASCVD or heart failure actually carry high long-term risk, since standard equations do not fully capture cumulative exposure to causal risk factors, genetic susceptibility, environmental influences or social determinants of health. Traditional calculators also perform poorly in younger adults, even though dyslipidemia is common long before the usual 40-to-70 age range. Heterozygous familial hypercholesterolemia affects about 1 in 250 to 300 people, yet it is frequently missed because many patients with very high LDL do not report a family history of hypercholesterolemia or early cardiovascular disease. The updated ACC/AHA guidance calls for screening beginning in young adulthood, lipid checks starting at age 19 and repeat assessment about every 5 years for people at average risk.

On treatment, the 2026 ACC/AHA guideline moves from a threshold-only approach to a hybrid strategy that combines explicit LDL goals, percentage reduction targets and individualized risk assessment. For example, in a middle-aged patient with risk-enhancing factors, an LDL of 140 mg/dl on a moderate-intensity statin and a calculated 10-year PREVENT risk of 18 percent, older guidance would mainly have emphasized stepping up to a high-intensity statin without setting a clear goal. The newer guidance favors defined LDL reduction targets and earlier use of combination therapy to reach them. If goals are not met, treatment can be escalated step by step with ezetimibe, PCSK9 inhibitors, bempedoic acid or inclisiran, with cost, access and patient preference explicitly considered. European and American Association of Clinical Endocrinology guidance instead supports earlier and more aggressive combination treatment tied to predefined thresholds, while AACE more clearly endorses bempedoic acid and is more cautious about inclisiran.

Evidence for earlier combination therapy has continued to grow. The RACING trial found that moderate-intensity statin plus ezetimibe was noninferior to high-intensity statin monotherapy for major cardiovascular outcomes, while achieving better LDL goal attainment and causing fewer discontinuations due to intolerance. IMPROVE-IT had already shown added benefit from ezetimibe on top of statin therapy in high-risk patients. Safety concerns about very low LDL have also eased: in FOURIER, evolocumab lowered median LDL to about 30 mg/dl and reduced major cardiovascular events, and extension data showing levels below 20 mg/dl did not reveal adverse neurological, hormonal or cardiometabolic effects. ODYSSEY OUTCOMES also demonstrated benefit with alirocumab in post-ACS patients who reached very low LDL, and the EBBINGHAUS substudy found no meaningful cognitive decline with intensive lowering. These findings support European targets below 55 mg/dl for very high-risk patients.

Coronary artery calcium scoring now has a larger, though still carefully limited, role. It is independently associated with 10-year ASCVD risk and is most useful for asymptomatic men aged 40 and older and women aged 45 and older at borderline risk when the decision to start a statin remains unclear. A score of zero can justify deferring therapy, while a score of 100 or more supports starting treatment. But because calcification appears late in atherosclerosis, the test is less informative in younger people, where a zero score can look reassuring even when lifetime risk is substantial. The review notes that no randomized trial has yet shown that calcium screening lowers heart attack or death rates; its value lies in risk prediction and treatment decisions rather than proven outcome benefit.

The authors also highlight several residual risk pathways beyond LDL. Lipoprotein(a) is a genetically determined causal risk factor that is largely unaffected by lifestyle and has both pro-atherogenic and pro-thrombotic effects. A level of 50 mg/dl, found in about 20 percent of people, is associated with roughly 40 percent higher relative risk than the population median. Statins and lifestyle changes have little effect on it, PCSK9 inhibitors lower it modestly, and lipoprotein apheresis remains the only FDA-approved option for high-risk patients with familial hypercholesterolemia and elevated Lp(a) who do not meet lipid goals. Antisense and siRNA drugs have reduced circulating Lp(a) by up to 80 percent with pelacarsen and by more than 90 percent with olpasiran in a dose-dependent way, but those studies did not test cardiovascular outcomes, so it remains unknown whether selective lowering reduces events. Inflammation is another modifier: in REPRIEVE, pitavastatin reduced major adverse cardiovascular events by 35 percent versus placebo in people with HIV, and JUPITER showed that moderate-intensity rosuvastatin significantly lowered major events in patients with normal LDL but elevated high-sensitivity C-reactive protein.

Triglycerides are another important piece of residual risk. Higher levels are well established as being linked to increased ASCVD risk and all-cause mortality, while a study in heart failure patients found a U-shaped relationship: triglycerides of 265.8 mg/dl or more were tied to ASCVD admission or death, whereas very low levels below 106.3 mg/dl were associated with higher heart failure readmission or mortality, possibly reflecting frailty or malnutrition. Traditional triglyceride-lowering drugs have had mixed cardiovascular results, with icosapent ethyl standing out in high-risk patients already taking statins. New therapies aimed at apolipoprotein C-III are advancing: plozasiran significantly lowered ApoC-III and triglycerides in severe hypertriglyceridemia in SHASTA-2, and the antisense drug olezarsen reduced triglycerides and acute pancreatitis compared with placebo.

Looking ahead, the review points to several investigational directions. Inclisiran, a small interfering RNA that targets hepatic PCSK9 synthesis, produces sustained LDL reductions of about 50 percent with twice-yearly dosing, but final cardiovascular outcomes data are still pending from ORION-4 and VICTORION-2P. Polygenic risk scores, which combine hundreds of thousands of common variants, identified 8 percent of the UK Biobank population as having about a threefold increased coronary artery disease risk similar to monogenic familial hypercholesterolemia, including people who would not be identified through LDL, blood pressure or family history alone. The authors caution, however, that predictive accuracy is weaker in non-European populations and that broader validation and fair implementation are needed before routine use. They also note that the article is a narrative review rather than a formal systematic review, so selection bias is possible, and that lipid guidance continues to change quickly as new evidence emerges.

Subject of Research: Modern lipid management and evolving guidelines for atherosclerotic cardiovascular disease prevention in primary care

Article Title: Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care

Article References: Carlson, A., Zayyad, Z. A., Driesenga, S., Boxley, P., Mishra, A., Uraizee, O., Ephrem, R., Zhang, R., Natsheh, Z., & Shroff, A. R. (2026). Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care. Cardiology and Therapy, 15(3), 481-501. https://doi.org/10.1007/s40119-026-00473-5

Image Credits: AI Generated

Keywords: LDL cholesterol, ASCVD prevention, lipoprotein(a), PREVENT risk model, coronary artery calcium, statin therapy, PCSK9 inhibitors, ezetimibe, apolipoprotein B, triglycerides, polygenic risk scores, primary care

Cite Scienmag News

Ophelia Keating. Scienmag. https://scienmag.com/cholesterol-care-moves-past-ldl-as-guidelines-embrace-lifetime-risk/

Ophelia Keating. "Cholesterol Care Moves Past LDL as Guidelines Embrace Lifetime Risk." Scienmag, https://scienmag.com/cholesterol-care-moves-past-ldl-as-guidelines-embrace-lifetime-risk/.